Related Experiment Video
Updated: Sep 27, 2026

Analysis of Group IV Viral SSHHPS Using In Vitro and In Silico Methods
Published on: December 21, 2019
Retroviruses have differing requirements for proteasome function in the budding process
David E Ott1, Lori V Coren, Raymond C Sowder
1AIDS Vaccine Program, SAIC-Frederick, Inc., National Cancer Institute at Frederick, Frederick, Maryland 21702-1201, USA. ott@ncifcrf.gov
Abstract:
Proteasome inhibitors reduce the budding of human immunodeficiency virus types 1 (HIV-1) and 2, simian immunodeficiency virus, and Rous sarcoma virus. To investigate this effect further, we examined the budding of other retroviruses from proteasome inhibitor-treated cells. The viruses tested differed in their Gag organization, late (L) domain usage, or assembly site from those previously examined. We found that proteasome inhibition decreased the budding of murine leukemia virus (plasma membrane assembly, PPPY L domain) and Mason-Pfizer monkey virus (cytoplasmic assembly, PPPY L domain), similar to the reduction observed for HIV-1. Thus, proteasome inhibitors can affect the budding of a virus that assembles within the cytoplasm. However, the budding of mouse mammary tumor virus (MMTV; cytoplasmic assembly, unknown L domain) was unaffected by proteasome inhibitors, similar to the proteasome-independent budding previously observed for equine infectious anemia virus (plasma membrane assembly, YPDL L domain). Examination of MMTV particles detected Gag-ubiquitin conjugates, demonstrating that an interaction with the ubiquitination system occurs during assembly, as previously found for other retroviruses. For all of the cell lines tested, the inhibitor treatment effectively inactivated proteasomes, as measured by the accumulation of polyubiquitinated proteins. The ubiquitination system was also inhibited, as evidenced by the loss of monoubiquitinated histones from treated cells. These results and those from other viruses show that proteasome inhibitors reduce the budding of viruses that utilize either a PPPY- or PTAP-based L domain and that this effect does not depend on the assembly site or the presence of monoubiquitinated Gag in the virion.
Insights
Proteasome inhibitors reduce budding for many retroviruses, including those with cytoplasmic assembly. However, some viruses like MMTV are unaffected, indicating complex interactions with the ubiquitination system.
Area of Science:
- Virology
- Molecular Biology
- Cell Biology
Background:
- Proteasome inhibitors are known to impede the budding of certain retroviruses, such as human immunodeficiency virus type 1 (HIV-1).
- The precise mechanisms and viral targets affected by proteasome inhibitors during retroviral budding remain incompletely understood.
Purpose of the Study:
- To investigate the impact of proteasome inhibitors on the budding of diverse retroviruses with varying Gag organization, late (L) domain usage, and assembly sites.
- To determine if proteasome inhibition affects viruses that assemble in the cytoplasm.
Main Methods:
- Treatment of various cell lines with proteasome inhibitors.
- Analysis of retroviral particle budding from treated cells.
- Examination of viral Gag-ubiquitin conjugates in viral particles.
- Assessment of proteasome and ubiquitination system activity via protein analysis.
Main Results:
- Proteasome inhibition decreased budding of murine leukemia virus and Mason-Pfizer monkey virus, both utilizing a PPPY L domain.
- Budding of mouse mammary tumor virus (MMTV), with an unknown L domain, was unaffected by proteasome inhibitors.
- Gag-ubiquitin conjugates were detected in MMTV particles, suggesting ubiquitination system involvement.
- Proteasome inhibitors effectively inactivated proteasomes and inhibited the ubiquitination system in treated cells.
Conclusions:
- Proteasome inhibitors reduce budding of retroviruses employing PPPY- or PTAP-based L domains, irrespective of their assembly site or Gag ubiquitination status.
- The effect of proteasome inhibitors on viral budding is virus-specific and may not universally apply to all retroviruses, even those with cytoplasmic assembly.
More Related Videos
09:38Identification of Nucleolar Factors During HIV-1 Replication Through Rev Immunoprecipitation and Mass Spectrometry
Published on: June 26, 2019
10:11Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes
Published on: September 27, 2014
Related Concept Videos
Inhibitors of Virion Maturation and Assembly
Retrovirus Life Cycles
Retroviruses
Size and Structure of Viral Genomes
Mechanisms of Retrovirus-induced Cancers
Mechanisms of Retrovirus-induced Cancers